Publications by authors named "M L Simonet"

Article Synopsis
  • The study aimed to evaluate how well cefazolin compares to cloxacillin for treating infective endocarditis caused by methicillin-sensitive Staphylococci (MSS).
  • Data were collected from patients treated in six French hospitals between 2014 and 2020, measuring treatment failure based on a variety of outcomes like death and relapse within 90 days.
  • Results showed no significant differences in treatment effectiveness or safety between the two antibiotics, indicating that cefazolin is similarly effective as cloxacillin for MSS endocarditis.
View Article and Find Full Text PDF

The spotted ratfish Hydrolagus colliei is the most common holocephalan species exhibited in aquaria worldwide for introducing deep-sea environments and raising awareness of their conservation. However, little is known about the biology of H. colliei.

View Article and Find Full Text PDF

The stopping of a planned motor response is called motor inhibitory control (IC) and allows humans to produce appropriate goal-directed behaviour. The ever-changing environment of many sports requires athletes to rapidly adapt to unpredictable situations in which split-second suppressions of planned or current actions are needed. In this scoping review, the approach of the PRISMA-ScR was used to determine whether sports practice develops IC and, if so, which sports factors are key to building IC expertise.

View Article and Find Full Text PDF

Higher cardiorespiratory fitness is associated with an increased ability to perform sustained attention tasks and detect rare and unpredictable signals over prolonged periods. The electrocortical dynamics underlying this relationship were mainly investigated after visual stimulus onset in sustained attention tasks. Prestimulus electrocortical activity supporting differences in sustained attention performance according to the level of cardiorespiratory fitness have yet to be examined.

View Article and Find Full Text PDF

Background: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not yet approved for AML and there were therefore no formal usage recommendations. Here we report the first study in a French cohort that assessed venetoclax in combination with existing treatments for AML under real-life conditions.

View Article and Find Full Text PDF